1533 Monrovia Avenue
90 articles with Biomerica Inc.
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Fiscal fourth quarter revenues increase 133.7% over the prior year Fiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods ® patent granted for Singapore
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors
Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of dedicated service, Ms. Moore has decided to retire and pursue personal interests
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests
Biomerica Inc. (NASDAQ: BMRA ) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that offers a revolutionary new way to treat patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application #16/385,322 contains numerous claims that broadl
Biomerica Inc. announced that it has filed a new three year shelf registration statement on Form S-3 with the United States Securities and Exchange Commission to replace its previous three year shelf registration statement, which was declared effective by the SEC in July 2017.
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced Biomerica 10-minute finger prick antibody tests already being sold outside of the US Biomerica has filed a provisional patent on technology to allow simplified blood collection
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial
Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology
Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution
New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick.
Biomerica, Inc. reported net sales of $3,967,712 for the nine months ending February 29, 2020, compared to $4,034,822 for the period ended February 28, 2019.
Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs
Biomerica Inc. (NASDAQ: BMRA ) today announced it has signed two separate definitive license agreements with Mount Sinai’s Icahn School of Medicine in New York
10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office
Biomerica Inc. announced that the Company completed a private placement of $2 million of convertible preferred stock with Palm Global Small Cap Master Fund LP.
Biomerica announced a net loss for the three months ended November 30, 2019 of $485,260, or $0.05 per share, versus a net loss of $477,244, or $0.05 per share, in the previous fiscal year during the same quarter.
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)
Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 for the same period in the previous year.
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity testing. The patent is expected to issue before September 2018.
Net sales were $3,058,119 for the six months ended November 30, 2017 compared to $2,842,317 for the same period in fiscal 2017.
China Food and Drug Administration (CFDA) Approves Biomerica Colorectal Screening Test to Help Identify the Early Warning Signs of Colorectal Cancer
The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer.
Biomerica Extends Exclusive License Agreement With Celtis Pharm (Telcon Pharmaceuticals) to December 2019
Previously announced Korean deal valued at up to $8.5 million.